IP Verse

Sulfonylureas And Related Compounds And Use Of Same - EP3259253

The patent EP3259253 was granted to The Provost on Jan 15, 2020. The application was originally filed on Feb 16, 2016 under application number EP16751821A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3259253

THE PROVOST
Application Number
EP16751821A
Filing Date
Feb 16, 2016
Status
Granted And Under Opposition
Dec 13, 2019
Grant Date
Jan 15, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANOct 15, 2020ELKINGTON AND FIFEADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTEP1236468
INTERNATIONAL-SEARCH-REPORTUS4018929
INTERNATIONAL-SEARCH-REPORTUS5169860
INTERNATIONAL-SEARCH-REPORTWO0119390
INTERNATIONAL-SEARCH-REPORTWO9832733
OPPOSITIONWO0119390
OPPOSITIONWO2016131098
OPPOSITIONWO9832733
SEARCHEP0885890

Non-Patent Literature (NPL) Citations (18) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- "2-Furansulfonamide, N-[[(l,2,3,5,6,7-hexahydro-s-indacen-4 yl)amino]carbonyl]-4-(1-hydroxy-l-methylethyl) - (CA INDEX NAME)", Registry, STN, (19980903), Database accession no. RN 210826-40-7, XP055745610-
OPPOSITION- D30 - OPPOSITION AGAINST EP3259253 B1 DECLARATION OF PROF LUKE O'NEILL-
OPPOSITION- M, Stocks, L. Alcaraz and E. Griffen, On Chemistry - On Medicinal Chemistry, Great Britain, Sci-Ink Limited, (20070000), pages 214 - 215, XP055745471-
OPPOSITION- Nathan Brown, Bioisosteres in Medicinal Chemistry, WILEY-VCH Verlag GmbH & Co. KGaA, (20120000), pages 3-20, 136 - 138, XP055745474-
OPPOSITION- Moritz Haneklaus, Luke Aj O’neill, Rebecca C Coll, "Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments", Current opinion in immunology, (20130200), vol. 25, no. 1, pages 40 - 45, XP055745589
OPPOSITION- Dempsey Colin; Coll Rebecca; Robertson Avril; Cooper Matthew; O'Neill Luke; Lynch Marina, "Cytokine release inhibitor drug, CRID3, inhibits the NLRP3 inflammasome in glia", Journal of Neuroimmunology, (20141015), vol. 275, no. 1, page 147, XP029083496
OPPOSITION- Mark A Febbraio, "Role of interleukins in obesity: implications for metabolic disease", Trends in Endocrinology and Metabolism, (20140600), vol. 25, no. 6, pages 312 - 319, XP055745491
OPPOSITION- Alex G. Baldwin, Brough David, Freeman Sally, "Inhibiting the Inflammasome: A Chemical Perspective", J. Med. Chem., (20150930), vol. 59, pages 1691 - 1710, XP055745542
OPPOSITION- David J. St. Jean, Fotsch Christopher, "Mitigating Heterocycle Metabolism in Drug Discovery", Journal of medical chemistry, (20120425), vol. 55, no. 13, pages 6002 - 6020, XP055745476
OPPOSITION- Deepak K Dalvie; Amit S Kalgutkar; Cyrus Khojasteh-Bakht S; Scott Obach R; John P O'donnell, "Biotransformation Reactions of Five-Membered Aromatic Heterocyclic Rings", CHEMICAL RESEARCH IN TOXICOLOGY, (20020300), vol. 15, no. 3, doi:10.1021/tx015574b, pages 269 - 299, XP055239789
OPPOSITION- Rebecca C Coll, Avril A B Robertson, Jae Jin Chae, Sarah C Higgins, Raúl Muñoz-Planillo, Marco C Inserra, Irina Vetter, Lara S Dungan, Brian G Monks, Andrea Stutz, Daniel E Croker, Mark S Butler, Moritz Haneklaus, Caroline E Sutton, Gabriel Núñez, Eicke Latz, Daniel L Kastner, Kingston H G Mills, Seth L Masters, Kate Schroder, Matthew A Cooper & Luke A J O’neill, "A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases", Nature, (20150216), vol. 21, no. 3, pages 248 - 257, XP055745537
OPPOSITION- Haitao Guo, Justin B Callaway & Jenny P-Y Ting, "Inflammasomes: mechanism of action, role in disease, and therapeutics", Nature Medicine, (20150700), vol. 21, no. 7, pages 677 - 687, XP055745593
OPPOSITION- Lisa M Mullen; Giselle Chamberlain; Sandra Sacre, "Pattern recognition receptors as potential therapeutic targets in inflammatory rheumatic disease", Arthritis Research & Therapy, (20150500), vol. 17, no. 1, doi:10.1186/s13075-015-0645-y, page 122, XP021223428
OPPOSITION- Rebecca C Coll; Luke A J O'neill, "The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes", PLoS One, (20111222), vol. 6, no. 12, doi:10.1371/journal.pone.0029539, page e29539, XP055474074
SEARCH- ABOU OUF A A ET AL, "THIOPHENE SULPHONYLUREAS STRUCTURALLY RELATED TO ANTIDIABETIC DRUGS", JOURNAL OF DRUG RESE, DRUG RESEARCH AND CONTROL CENTER, GIZA, EG, (19740101), vol. 6, no. 2, ISSN 0368-1866, pages 123 - 129, XP009011580 [X] 1,3,5-7,9,14-17 * page 126; table I *-
SEARCH- EGGLER J F ET AL, "Synthesis of covalent (14C)-labeled diarylsulfonylurea (DASU) inhibitors of the processing and release of IL-1", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, JOHN WILEY, GB, (20020801), vol. 45, no. 9, doi:10.1002/JLCR.602, ISSN 0362-4803, pages 785 - 794, XP002264662 [X] 1,3-7,14-17 * page 786; figure 1 *
SEARCH- HOWBERT J J ET AL, "NOVEL AGENTS EFFECTIVE AGAINST SOLID TUMORS: THE DIARYLSULFONYLUREAS. SYNTHESIS, ACTIVITIES, AND ANALYSIS OF QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, (19900101), vol. 33, doi:10.1021/JM00171A013, ISSN 0022-2623, pages 2393 - 2407, XP000919053 [X] 1,3,5-6 * page 2394 - page 2395; compounds 1,17,104,139,140 *
SEARCH- FRANK J. URBAN ET AL, "Novel Synthesis of 1-(1,2,3,5,6,7-Hexahydro- s -indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]urea, an Anti-inflammatory Agent", SYNTHETIC COMMUNICATIONS, PHILADELPHIA, PA; US, (20030701), vol. 33, no. 12, doi:10.1081/SCC-120021029, ISSN 0039-7911, pages 2029 - 2043, XP055306651 [X] 1-8,10-17 * page 2029; compound 1 * [I] 9

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents